Table 1.
Baseline characteristics of the Translink cohort at inclusion
| Group A | Group B1 | Group B2 | |||||
|---|---|---|---|---|---|---|---|
| Characteristics | BHV SVD patients | BHV patients | Controls | P | BHV patients | Controls | P |
| n = 174 | n = 500 | n = 118 | n = 752 | n = 124 | |||
| Age (years) | 77 ± 10 | 74 ± 8 | 64 ± 11 | <0.001 | 78 ± 8 | 70 ± 11 | <0.0001 |
| Male, n (%) | 92 (52.9) | 302 (60.5) | 93 (78.8) | <0.001 | 508 (67.6) | 102 (82.3) | 0.001 |
| SBP, mmHg | 134 ± 21 | 132 ± 17 | 131 ± 17 | 0.93 | 138 ± 18 | NA | |
| NYHA class 2–4, n (%) | 145 (84.3) | 437 (87.4) | 77 (65.3) | <0.001 | 246 (34.1) | 30 (24.4) | 0.034 |
| BMI, kg m−2 | 28 ± 5 | 28.1 ± 4.4 | 27.6 ± 4.2 | 0.55 | 28 ± 4 | 28 ± 4 | 0.158 |
| Tobacco, n (%) | 60 (34.5) | 179 (35.8) | 65 (55.1) | <0.001 | 234 (31.2) | 31 (25.0) | 0.164 |
| Hypertension, n (%) | 139 (79.9) | 401 (80.2) | 89 (75.4) | 0.25 | 619 (82.4) | 92 (12.9) | 0.030 |
| Diabetes, n (%) | 49 (28.2) | 127 (25.4) | 29 (24.6) | 0.85 | 196 (26.1) | 32 (25.8) | 0.945 |
| Dyslipidemia, n (%) | NA | 18 (15) | 46 (16) | 0.36 | NA | NA | |
| Creatinine clearance, ml/min/1.73 m−2 | 62 ± 25 | 74 ± 21 | 85 ± 23 | 0.26 | 67 ± 23 | 83 ± 26 | 0.061 |
| CPB time, min | NA | 111 ± 59 | 102 ± 49 | 0.58 | NA | NA | |
| PPM | |||||||
| Moderate, n (%) | NA | 171 (34.2) | NA | NA | NA | ||
| Severe, n (%) | NA | 15 (3.0) | NA | NA | NA | ||
| Intervention, n (%) | |||||||
| BHV | 170 (97.7) | 429 (85.8) | – | 746 (99.2) | – | ||
| TAVI | 4 (2.3) | 71 (14.2) | – | 6 (0.8) | – | ||
| CABG | – | 95 (19.0) | 61 (51.7) | 193 (25.7) | 43 (34.7) | ||
| MHV | – | – | 57 (48.3) | – | 81 (65.3) | ||
| Center, n (%) | |||||||
| Nantes University Hospital, France | 125 (71.8) | 185 (37.0) | 34 (28.8) | 317 (42.6) | 12 (9.7) | ||
| Azienda Ospedaliera di Padova, Italy | 8 (4.6) | 141 (28.2) | 25 (21.2) | 184 (24.7) | 55 (44.4) | ||
| University Hospital Vall D’Hebron, Spain | 35 (20.1) | 123 (24.6) | 41 (34.7) | 174 (23.4) | 37 (29.8) | ||
| Bellvitge University Hospital, Spain | 6 (3.4) | 51 (10.2) | 18 (15.2) | 70 (9.4) | 20 (16.1) | ||
| St Boniface Hospital, Winnipeg, Canada | – | – | – | 7 (0.9) | – | ||
| 0.02 | <0.001 | ||||||
Group A: SVD patients; Group B1: first-time BHV recipient or control MHV or CABG treated patients; Group B2: BHV recipients ≥4 years before inclusion and controls (MHV recipients or patients treated with CABG ≥4 years before inclusion). Comparisons between groups were performed using Student’s t-tests or chi-squared tests for continuous or categorical variables, respectively. NA, not applicable; NYHA, New York Heart Association; SBP, systolic blood pressure.